Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 78.57%.

  • China Pharma Holdings' EBITDA Margin rose 105400.0% to 78.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 81.63%, marking a year-over-year increase of 3900.0%. This contributed to the annual value of 107.5% for FY2024, which is 618700.0% down from last year.
  • China Pharma Holdings' EBITDA Margin amounted to 78.57% in Q3 2025, which was up 105400.0% from 49.53% recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' EBITDA Margin ranged from a high of 13.81% in Q1 2023 and a low of 160.4% during Q2 2024
  • In the last 5 years, China Pharma Holdings' EBITDA Margin had a median value of 60.96% in 2022 and averaged 65.62%.
  • As far as peak fluctuations go, China Pharma Holdings' EBITDA Margin crashed by -744100bps in 2024, and later surged by 1108700bps in 2025.
  • Over the past 5 years, China Pharma Holdings' EBITDA Margin (Quarter) stood at 28.97% in 2021, then fell by -28bps to 37.0% in 2022, then tumbled by -39bps to 51.46% in 2023, then plummeted by -145bps to 125.87% in 2024, then skyrocketed by 38bps to 78.57% in 2025.
  • Its EBITDA Margin stands at 78.57% for Q3 2025, versus 49.53% for Q2 2025 and 68.47% for Q1 2025.